2 terminated, 2 withdrawn, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Costantine Albany: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Rolapitant, Palonosetron, Olanzapine - Germ Cell Tumor | Phase 2 | Withdrawn | Costantine Albany | 2018-05-01 | 2019-05-22 | |
| Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy Blood sample collection, Report of peripheral neuropathy after cisplatin therapy - Peripheral Nervous System Diseases, Testicular Neoplasms | Withdrawn | Costantine Albany | 2017-12-01 | 2018-02-28 | ||
| Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor EORTC QLQ-CIPN20 - Testicular Germ Cell Tumor | Completed | Costantine Albany | 54 | 2015-07-01 | 2020-09-22 | |
| Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain Morphine, Oxcarbazepine - Cancer | Phase 1 | Terminated | Costantine Albany | 1 | 2014-03-06 | 2017-01-31 |
| OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone OGX-427, Abiraterone Acetate, Prednisone - Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer | Phase 2 | Terminated | Costantine Albany | 72 | 2012-12-01 | 2022-07-11 |
Cancer Pain (1) · Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Peripheral Nervous System Diseases (1) · Prostatic Neoplasms (1) · Testicular Germ Cell Tumor (1) · Testicular Neoplasms (1)
Abiraterone Acetate (1) · Dexamethasone (1) · Morphine (1) · Olanzapine (1) · Oxcarbazepine (1) · Palonosetron (1) · Prednisone (1) · Steroids (1) · apatorsen (1) · rolapitant (1)
United States (4) · Canada (1)